Janssen Pharmaceutical Inc., a subsidiary of Johnson & Johnson, has settled lawsuits accusing it of using underhanded and illegal practices to market anti-psychotic drug Risperdal.
Pharmaceutical manufacturers are barred from promoting their products for uses outside of those for which they have Food and Drug Administration approval. Risperdal is approved to treat solely schizophrenia and bipolar disorder.
The lawsuits against the company accused it of ghost writing articles in medical journals promoting the drug’s effectiveness as a treatment for dementia. The company settled the claims outside of court last week and will pay out $181 million to 36 states.
When product manufacturers use misguidance to increase their sales, they can be held accountable if someone’s skewed expectations of their product cause them to become injured. If you have been hurt as a direct result of being misled by a product’s marketing, contact the product liability attorneys of Yearout & Traylor, P.C., at 205.414.8160.